ANAB · AnaptysBio, Inc. · Stock research

Current Thesis

The April 2026 spin-off rewrote this name and the rewrite still governs. AnaptysBio shed its clinical pipeline (rosnilimab, ANB033, ANB101) plus $100M cash into First Tracks Biotherapeutics (Nasdaq: TRAX, 1:1 distribution, record date 2026-04-06, spin completed 2026-04-20) and now trades as a pure-play royalty stub on two assets: Jemperli (dostarlimab) via GSK and imsidolimab via Vanda. The whole equity collapses into one binary that is no longer weeks away the Tesaro/GSK Delaware Chancery trial runs 2026-07-14 to 2026-07-17, one to three trading days from the current session, deciding whether Anaptys recaptures full Jemperli economics (reversion) and preserves its 8–25% royalty rate. The 2026-04-24 pre-trial ruling dismissed Tesaro's anticipatory-breach claim and rejected its royalty-reduction request, tilting legal odds toward Anaptys and popping the stock +12% on 2026-04-27. Since then the tape round-tripped from the $73.30 52-week high back to ~$50, the floor of the $50–140 analyst band. This is a coin-flip with a date stamped on it, now entering its blackout.

Bullish and bearish views on AnaptysBio, Inc.

The model's bull view on AnaptysBio, Inc. (ANAB), in brief: Royalty annuity on a growing PD-1. Jemperli/dostarlimab pays 8–25% of net sales with composition-of-matter coverage to 2035 (US) / 2036 (EU) / 2037 (JP) a non-dilutive recurring stream on a GSK oncology franchise still adding indications. The reversion call option. A favorable… The bear view: The thesis is one legal verdict. The 2026-07-14/17 trial is the entire story; an adverse ruling vaporizes the reversion option and reopens Tesaro's royalty-cut path. Court outcomes are not modellable into the date this is a bet on a bench ruling with no edge to model. Momentum… Both cases follow in full.

Bull Case

• Royalty annuity on a growing PD-1. Jemperli/dostarlimab pays 8–25% of net sales with composition-of-matter coverage to 2035 (US) / 2036 (EU) / 2037 (JP) a non-dilutive recurring stream on a GSK oncology franchise still adding indications.
• The reversion call option. A favorable 2026-07-14/17 verdict can recapture full Jemperli economics, not merely preserve the royalty. The 2026-04-24 Delaware ruling already knocked out Tesaro's anticipatory-breach theory and rejected the royalty cut, carrying legal momentum into the bench trial.
• Clean post-spin structure. Offloading the cash-burning pipeline and $100M to TRAX (completed 2026-04-20) removed clinical-trial dilution risk; what remains is a royalty book plus a legal option with no R&D drain.
• Second royalty trigger dated. Imsidolimab (Vanda) carries an FDA action date of 2026-12-12 for generalized pustular psoriasis, with Phase III data published in NEJM (~2026-04-29). Approval adds a stream at no incremental ANAB cost.
• Sell-side breadth, no sells. HC Wainwright assumed Buy → $95 (2026-06-10) joins Piper Overweight → $93 (2026-05-04) and Leerink Outperform → $85 (2026-04-28); average target near $80 vs ~$50 spot (~+55%), high estimate $140, zero published sells.

Bear Case

• The thesis is one legal verdict. The 2026-07-14/17 trial is the entire story; an adverse ruling vaporizes the reversion option and reopens Tesaro's royalty-cut path. Court outcomes are not modellable into the date this is a bet on a bench ruling with no edge to model.
• Momentum leg spent. Price surrendered the post-ruling spike and the $73.30 high, back at ~$50 with no trending tape. The next directional move arrives as a gap weeks out.
• spot trades at the bottom of the target range while none of the bulls' upside is being priced.
• Single-counterparty dependence. Royalty value rides entirely on GSK's execution of Jemperli any deprioritization or label setback hits the annuity, with no pipeline left to offset it.
• Ruling may lag the hearing. A Chancery post-trial opinion can arrive days to weeks after closing arguments; the 7/14–17 window may deliver headline volatility without a final verdict, extending the uncertainty rather than resolving it on schedule.

Setup & Price Structure

Beta 0.41 this trades on legal and royalty headlines, not on the index. Spot near the last $50.37 reference (2026-06-05) sits at the floor of the $50–140 analyst band and just above the ~$40 gap left by the 2026-04-24/27 court-ruling pop. The post-spin base has held roughly $48–52 for weeks; the $73.30 52-week high is a distant ceiling after a full round-trip. There is no momentum structure to lean on no rising 20-EMA to defend, no breakout shelf reclaiming highs. The verdict is expected to print as a violent ±20–40% gap rather than a trend. A trade into the print is a directional bet on a Delaware bench ruling; sizing risk is binary, and the cleanest stance is to stand aside until the legal outcome is known and a fresh base forms.

Catalyst Calendar (next 30 days)

• Post-trial (timing uncertain): a Chancery written opinion may follow the hearing by days to weeks; a same-week verdict is not guaranteed. Treat any date after 7/17 as open until an opinion posts.
• 2026-12-12 (beyond window): imsidolimab FDA action date (Vanda) for generalized pustular psoriasis the second royalty trigger, well outside 30 days but the next dated event after the trial.

Elapsed catalysts

• 2026-07-13 (Mon): final session before trial; pre-verdict positioning into thin liquidity. _(passed 6d ago)_
• 2026-07-14 → 2026-07-17: Tesaro/GSK vs Anaptys Delaware Chancery trial on Jemperli royalty reversion and rate preservation the single binary. Expect intra-week volatility on trial developments. _(passed 2d ago)_

What Would Change Our Mind

A favorable 2026-07-14/17 ruling that confirms Jemperli reversion and locks the 8–25% royalty re-rates the stub toward the ~$80 average target and would justify chasing strength once price reclaims the post-spin base on a clean breakout. The bearish break: a daily close below $40 fills the April court-ruling gap and breaks the post-spin base, signalling the market is pricing an adverse verdict. A written opinion denying reversion or reopening the Tesaro royalty-cut path is the fundamental invalidation regardless of price. Absent a verdict, there is nothing to trade the name is dead tape until Delaware speaks.

Correlation Notes

Correlation to broad equity beta is low (0.41); this is an idiosyncratic legal special situation, not a theme vehicle. The old biotech-precision / SGMT peer-cluster momentum framing left with the TRAX spin-off and no longer applies the name should not be credited with pipeline optionality or clinical-catalyst beta. The only meaningful external dependencies are GSK's Jemperli commercial trajectory (the royalty base) and Vanda's imsidolimab FDA path (2026-12-12). Royalty-name comps such as XOMA Royalty move on similar single-asset legal/royalty headlines rather than sector flow. Into the trial, ANAB's move will be governed by Delaware, uncorrelated to sector or index flow.